Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.35 |
| ▸ | AGER | Q15109 | 1/20 | 0.35 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4574789 | 0.94 | ALDH1A1 (0.40) | CYP2D6CYP1A2HTR6CYP3A4ALDH1A1 | |
| SCHEMBL3454507 | 0.79 | CYP2D6 (0.44) | CYP2D6CYP1A2HTR6CYP3A4GAA | |
| SCHEMBL24360805 | 0.79 | POLB (0.43) | CYP3A4GAAALDH1A1TSHRPOLB | |
| SCHEMBL5437406 | 0.78 | ALDH1A1 (0.46) | CYP2D6CYP1A2CYP3A4GAAALDH1A1 | |
| SCHEMBL10279957 | 0.78 | ALDH1A1 (0.46) | CYP2D6CYP1A2CYP3A4GAAALDH1A1 | |
| SCHEMBL14778351 | 0.77 | GAA (0.43) | CYP3A4CYP2C19GAAALDH1A1ACHE | |
| SCHEMBL4125553 | 0.77 | GAA (0.43) | CYP2D6CYP3A4CYP2C19GAAALDH1A1 | |
| SCHEMBL19520992 | 0.76 | GAA (0.42) | CYP3A4CYP2C19GAAALDH1A1ACHE | |
| SCHEMBL14780181 | 0.73 | TSHR (0.45) | CYP2D6CYP1A2CYP3A4GAAALDH1A1 | |
| SCHEMBL4578793 | 0.73 | ALDH1A1 (0.49) | CYP2D6CYP1A2CYP3A4GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102232076-B | Pyrrolopyrazinyl urea kinase inhibitors | HOFFMANN LA ROCHE | 2014-12-31 | — | — | CN | disclosed |
| US-8222404-B2 | [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8097613-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2373653-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2009152166-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20080275032-A1 | Pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| WO-2008082725-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116077-A1 | [1,2,4]THIADIAZIN-3-YL ACETIC ACID COMPOUND[[S]] AND METHODS OF MAKING THE ACETIC ACID COMPOUND | ACMSD, ACACA, ALDH1A1 | CYP2D6 754/4885CYP1A2 28/4885HTR6 3135/4885 |
| US-20080275032-A1 | Pyridazinone compounds | HAVCR2, PLPBP, CYP3A43 | CYP2D6 15/4885CYP1A2 30/4885HTR6 922/4885 |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | CYP2D6 3250/4885CYP1A2 2869/4885HTR6 4652/4885 |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | CYP2E1, CYP1A1, CYP1B1 | CYP2D6 144/4885CYP1A2 4/4885HTR6 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.